1. Highest quarterly revenue of ₹132.6 Cr, growth of 56% YoY 2. EBITDA grew by 41% YoY to ₹23.8 Cr
3. robust revenue gains driven by higher contribution from recently commissioned phase I & II expansions at Dahej SEZ
4. EBITDA performance includes transient cost impact related to Phase I & II expansion. This will be neutralised once the new plants operate at optimal utilisation levels. 5. Mahape and Vadodara continue at high utilisation levels.
6. Domestic revenue contribution stood at 55%, rest 45% were export oriented 7. Demand for Lithium-based chemicals tends to be strong in Q4 as demand from the HVAC segment.
Business strategy
1. Aggregate revenue target of ₹750 Cr for FY24 including contribution of new lithium segment. 2. Phase 1 capex is used more on agro intermediates and phase 2 has pharma molecules and bromine derivatives
3. September FY23 should see full utilisation and revenue guidance of ₹650-₹675 Cr by Q2FY23 is anticipated 4. FY24 guidance may change depending on existing performance
42%( +/- 2%) gross margins level are sustainable
5. Lithium carbonate prices went up to $15-$18/ kg and are expected to rise in the next few quarters. Most of the incremental prices are passed on to customers. 6. Demand for electrolytes will be more on the renewable energy storages and hydrogen production facility
7. Different batteries have different cathode chemistry, this determines the composition of electrolytes and solvent in the battery. For every consumer the product is similar but not identical 8. Also looking for opportunities in lithium based battery additives
9. Electrolyte prices are different in Japan, Europe and China.
Segmental performance
1. 79% of revenues for Q3FY22 were contributed from the organic segment with growth of 53% YoY 2. Rest 21% is contributed from the inorganic with growth of 70% YoY
3. Early stage projects in CSM is undertaken
Capex
1. New lithium capex is expected to be commercialised by Sep FY23
The volumes at Dahej are ramping up for phase 1 and phase 2 expansions
2. Three more capex under consideration after the lithium facility
i) Large capex for electrolytes at karkhadi plant (depending on PLI scheme benefits and customer response for electrolyte products) 15-18 months is required to setup the facility
ii)Lithium salts at Dahej (decision to be considered post June FY23 and construction should be completed within ) 10-12 months is required to setup the facility
iii) Increase in organic capacity (decision to be considered by Sep-March period FY23) 12-15 months is required to setup the organic MPP
Expecting ₹50-₹100 Cr capex in the first phase.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenue for the quarter is ₹238.4 Cr (2.9% decline YoY). EBITDA for the quarter was ₹34.2 Cr (26.8% decline YoY) with an EBITDA margin of 14.3%.
2. They are facing supply chain issues due to raw material volatility and high logistics cost. They also benefited in the last few quarters due to raw material hedging for key ingredients, but those contracts expired in Q2 which caused a decline in margins.
They are holding higher inventory in case of possible future disruptions. 3. Currently profitability is low due to costs associated with commercialization on Unit 3. They expect more volumes from Unit 3 in the coming quarters.
1. The company has announced a buyback of ₹352 Cr including taxes. Including dividend, total payout to the shareholder for the financial year is at ₹434 Cr
2. Emerging Markets business (Branded Generics) - Spread across Asia and Africa and contributes 41% of revenues. Exports to these markets were ₹361 Cr (26% growth YoY).
Sales to Asia were ₹194 Cr (1% decline YoY). Sales to Africa were ₹167 Cr (87% growth YoY) however growth looks higher due to low base effect.
3. US Generic Business - Contributed 22% of revenues. Sales were ₹166 Cr(3% growth YoY).
1. The revenue for Q3FY22 grew by 22% QoQ to ₹255 Cr from ₹208.8 Cr in the previous quarter.
2. Gross margins stood at 37% in Q3FY22 compared to 40.6% in previous quarter, degrowth of (-362 bp)
3. 53.05% contribution of revenue from exports and 46.9% from domestic markets
4. Top 10 products contributed 65%+ revenues in 9MFY22
5. The contracts with Nippon Kayaku and a japanese company are performing well, the clients are satisfied with the product quality and high demand for molecules is anticipated